Table 3. Statistically significant association between seven potential metabolites and cancers.

Cancer type	Metabolite	Included SNP	IVW			MR-Egger			Weighted median
			OR (95% CI)	P value		OR (95% CI)	P value		OR (95% CI)	P value
Breast cancer	3-dehydrocarnitine	22	0.88 (0.78–0.98)	0.0194		0.77 (0.60–0.995)	0.047623		0.81 (0.70–0.95)	0.00790012
ER− breast cancer	1-oleoylglycerophosphocholine	16	1.38 (1.17–1.62)	0.0001		1.44 (1.05–1.99)	0.026764		1.36 (1.07–1.73)	0.01233648
	Salicylate	19	1.04 (1.01–1.06)	0.0009		1.05 (1.02–1.08)	0.002736		1.05 (1.02–1.09)	0.00102991
Lung cancer	Leucylalanine	19	1.16 (1.01–1.32)	0.031		1.70 (1.11–2.61)	0.017587		1.37 (1.12–1.66)	0.0019708
Squamous cell lung cancer	Octanoylcarnitine	17	0.74 (0.55–0.98)	0.038		0.53 (0.29–0.95)	0.036358		0.58 (0.36–0.92)	0.0204581
Ovarian cancer	Ibuprofen	101	0.96 (0.93–0.99)	0.007		0.92 (0.85–0.99)	0.033462		0.95 (0.91–0.995)	0.03205872
	Leucylalanine	19	0.96 (0.93–0.99)	0.007		0.92 (0.85–0.99)	0.033462		0.95 (0.91–0.995)	0.03205872

IVW, inverse variance weighted; MR, Mendelian randomization; ER, estrogen receptor; SNP, single nucleotide polymorphism.